SCHEMBL3765872

SCHEMBL3765872

O=C(CN1CCN(c2cnc(-c3ccc(F)c(Cl)c3)cn2)CC1)N1CCN(C2CCC2)CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
GRIN2B Q13224 7/20 0.43
HRH3 Q9Y5N1 2/20 0.42
MGLL Q99685 2/20 0.40
GRM5 P41594 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
GFER P55789 1/20 0.38
CCR2 P41597 1/20 0.38
KCNH2 Q12809 1/20 0.38
DPP4 P27487 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3779465 0.93 MEN1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3763107 0.92 HRH3 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3776002 0.92 MEN1 (0.43) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3770437 0.90 GRM5 (0.49) GRIN2BHRH3GRM5KCNH2
SCHEMBL3774286 0.89 HRH3 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3769414 0.88 GRM5 (0.42) NPSR1GRIN2BHRH3GRM5CYP11B1
SCHEMBL3767426 0.88 KMT2A (0.48) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3775676 0.87 MAPT (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3774094 0.87 MEN1 (0.42) MEN1KMT2ASMN1; SMN2ALDH1A1MAPT
SCHEMBL3769085 0.87 HRH3 (0.50) SMN1; SMN2ALDH1A1MAPTHRH3CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 MEN1 3270/4885KMT2A 242/4885SMN1; SMN2 4282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.